γ-Tocotrienol
Based on 4 publication(s) in Google Scholar
γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment.
For research use only. We do not sell to patients.
- Purity: 99.67%
- CAS No.: 14101-61-2
- Formula: C28H42O2
- Molecular Weight:410.63
-
Storage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) γ-Tocotrienol
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF-10A | IC50 |
4.4 μM
Compound: 1
|
Antiproliferative activity against human MCF10A cells by MTT assay
Antiproliferative activity against human MCF10A cells by MTT assay
|
[PMID: 23274571] |
| MCF7 | IC50 |
11.4 μM
Compound: 2
|
Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
|
[PMID: 20022507] |
| MCF7 | IC50 |
7.1 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells by MTT assay
Antiproliferative activity against human MCF7 cells by MTT assay
|
[PMID: 23274571] |
| MDA-MB-231 | IC50 |
>10 μM
Compound: 2
|
Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay
|
[PMID: 20022507] |
| MDA-MB-231 | IC50 |
>40 μM
Compound: 1
|
Antimigratory activity against human MDA-MB-231 cells after 24 hrs by wound-healing assay
Antimigratory activity against human MDA-MB-231 cells after 24 hrs by wound-healing assay
|
[PMID: 23274571] |
| MDA-MB-231 | IC50 |
9.4 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
|
[PMID: 23274571] |
γ-Tocotrienol (25 μM; 24 h) effectively inhibits the expression levels of mdr1 mRNA and P-gp protein, (25 μM and 50 μM; 24 h) suppresses mdr1 promoter activity and the efflux activity of P-gp as well[2].
γ-Tocotrienol (25 μM and 50 μM; 24 h) reduces the activation of NF-κB signaling pathway and the transcriptional activity of NF-κB[2].
γ-tocotrienol (50 μM; 48 h) effectively inhibits the process of nuclear translocation of p65 which was induced by TNFα[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7/Adr cells
-
Concentration:50 μM
-
Incubation Time:48 hours
-
Result:Decreased the red fluorescence of p65 in the nucleus, indicating nuclear translocation inhibiton of p65 induced by TNFα.
GT3-Nano (50 mg/kg; i.v.; ) can facilitate rapid recovery of hematopoietic components in mice treated with the endoradiotherapeutic agent 153Sm-EDTMP[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57/BL6 mice (6-8 weeks old) treated with the whole-body irradiation[3]
-
Dosage:16, 24, 32, and 50 mg/kg
-
Administration:Intravenous injection; observed mice for 100 days
-
Result:Demonstrated dose-dependent radioprotection, achieving 90% survival at 50 mg/kg against lethal 9-Gy of total-body irradiation (TBI).
And upregulated progenitor bone marrow cells MPP2 and CMP in GT3-Nano-treated mice.
Chemical Information
-
CAS No. 14101-61-2
-
Appearance Liquid (Density: 0.964±0.06 g/cm3)
-
Molecular Weight 410.63
-
Formula C28H42O2
-
Color Colorless to light yellow
-
SMILES
OC1=C(C)C(C)=C2C(CC[C@](CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C)(C)O2)=C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Effects of altering the pullulan/zein ratio on emulsion electrospinning of palm tocotrienol. [Abstract]2025 Sep 19;329(Pt 1):147791. PMID: 40976294 -
-
-
Solvent & Solubility
DMSO : 100 mg/mL (243.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.09 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.09 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. M A Newaz, et al. Nitric Oxide Synthase Activity in Blood Vessels of Spontaneously Hypertensive Rats: Antioxidant Protection by Gamma-Tocotrienol. J Physiol Pharmacol. 2003 Sep;54(3):319-27. [Content Brief]
[2]. Ding Y, et al. γ-Tocotrienol reverses multidrug resistance of breast cancer cells through the regulation of the γ-Tocotrienol-NF-κB-P-gp axis. J Steroid Biochem Mol Biol. 2021 May;209:105835. [Content Brief]
[3]. Lee SG, et al. γ-Tocotrienol-Loaded Liposomes for Radioprotection from Hematopoietic Side Effects Caused by Radiotherapeutic Drugs. J Nucl Med. 2021 Apr;62(4):584-590. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4353 mL | 12.1764 mL | 24.3528 mL | 60.8821 mL |
| 5 mM | 0.4871 mL | 2.4353 mL | 4.8706 mL | 12.1764 mL | |
| 10 mM | 0.2435 mL | 1.2176 mL | 2.4353 mL | 6.0882 mL | |
| 15 mM | 0.1624 mL | 0.8118 mL | 1.6235 mL | 4.0588 mL | |
| 20 mM | 0.1218 mL | 0.6088 mL | 1.2176 mL | 3.0441 mL | |
| 25 mM | 0.0974 mL | 0.4871 mL | 0.9741 mL | 2.4353 mL | |
| 30 mM | 0.0812 mL | 0.4059 mL | 0.8118 mL | 2.0294 mL | |
| 40 mM | 0.0609 mL | 0.3044 mL | 0.6088 mL | 1.5221 mL | |
| 50 mM | 0.0487 mL | 0.2435 mL | 0.4871 mL | 1.2176 mL | |
| 60 mM | 0.0406 mL | 0.2029 mL | 0.4059 mL | 1.0147 mL | |
| 80 mM | 0.0304 mL | 0.1522 mL | 0.3044 mL | 0.7610 mL | |
| 100 mM | 0.0244 mL | 0.1218 mL | 0.2435 mL | 0.6088 mL |